HPV: Page 2

Mel-Mont validates self-sampling kit
Norwegian researchers tested the kit's performance in a group of 500 women at detecting rates of genital HPV infection compared to clinician-collected samples. The study found "fair agreement" of HPV positivity rates between the two methods, according to the authors. The study was published in BMC Infectious Diseases.
August 4, 2021
2020 07 29 23 56 6775 Hpv Infection 400
Sysmex Inostics touts liquid biopsy findings at ASCO
The featured data will show how the company's SafeSEQ cfHPV-DNA Test (HPV-SEQ) detects cell-free HPV DNA, enabling monitoring for patients with HPV and oropharyngeal squamous cell carcinoma (OPSCC), a type of head and neck cancer.
June 3, 2021
2020 02 05 22 27 6689 Head Neck 400
BD seeks FDA OK to use more samples with HPV test
The company submitted a premarket approval supplement to the agency because it would expand the sample claims that can be used with the HPV assay. Currently, the assay is approved for use with BD's SurePath vial for the detection of HPV.
September 22, 2020
2019 08 20 21 56 4986 Becton Aacc 2019 400
ACS cervical cancer guidelines disappoint some testing firms
The current standard of care is to use the Pap test for women ages 21 to 29 and a combination of both the Pap test and HPV test (cotesting) for women between the ages of 30 and 65. The ACS guidelines, which were published July 30, would shift to HPV testing only, and Hologic claims this would erode access to preventative healthcare and could sow confusion among women and their healthcare providers.
July 30, 2020
2019 02 01 17 54 2200 Hologic Rsna 2018 400
National cervical cancer screening guidelines shift to primary HPV testing
The ACS published a 2020 update to guidelines for cervical cancer screening for individuals at average risk in its publication CA: A Cancer Journal for Clinicians online July 30. Guidelines were last updated in 2012.
July 30, 2020
2020 07 29 23 56 6775 Hpv Infection 400
BD's expanded genotype HPV test gets FDA nod
The BD Onclarity HPV assay individually identifies and reports genotypes beyond 16, 18, and 45. It also identifies and reports on genotypes 31, 51, 52, 33/58, 35/39/68, and 56/59/66, according to the company.
July 22, 2020
2020 07 22 22 14 9137 Bd Onclarity 400
Most Popular
Researchers find hidden bacteria that pose antimicrobial resistance risk to hospital patients
Quest Diagnostics Q4 revenues down 15% on COVID testing but base business grew
SD Biosensor, SJL Partners complete acquisition of Meridian Bioscience
OIG report outlines challenges with CDC-supported COVID-19 vaccination programs
Roche reports flat diagnostics revenue growth for 2022
Duke University developing blood test to detect osteoarthritis progression in the knee
HPV, Pap cotesting best for cervical cancer detection in Quest study
Cotesting involves Pap and HPV screening using the same specimen. A new study of women 30 years or older by researchers at Quest Diagnostics and the University of Pittsburgh Medical Center found that cotesting outperformed HPV or Pap testing alone for detecting precancer or cancer. In the retrospective study, the researchers evaluated deidentified results for tests conducted between 2010 and 2018 by Quest in 13.6 million women; 8,059 had precancers and 1,259 were subsequently diagnosed with cervical cancer.
July 8, 2020
2019 05 17 20 14 3434 Uterus Cervix 400
Machine learning could 'transform' cervical cancer screening, NCI researchers report
The NCI researchers described positive experiences with Cytoreader, an automated system for evaluating digital dual-stained whole-slide images for the protein biomarkers p16 and Ki-67, using data from three epidemiology studies of patients with cervical and anal cancers who were positive for human papillomavirus (HPV). The automated system assesses the number of dual-stained positive cells and flags the ones that exceed predefined cutoff points.
June 25, 2020
2020 06 24 23 01 2082 2020 06 25 Ai Dual Stain Image 400
Could cervical cancer be eliminated in 20 years?
The findings suggest a way for the U.S. clinical community to actively respond to the World Health Organization's (WHO) 2018 charge to eliminate cervical cancer as a public health problem, wrote a team led by Emily Burger, PhD, of the Harvard T.H. Chan School of Public Health in Boston. The WHO's cervical cancer incidence target is four or fewer cases per 100,000 women-years.
February 10, 2020
2019 05 17 20 14 3434 Uterus Cervix 400
Naveris blood test spots recurrence of HPV cancers
The test is designed to identify tumor-modified viral HPV DNA. The prospective study, conducted by lead author Dr. Bhisham Chera of the University of North Carolina School of Medicine and colleagues, included 115 patients treated for HPV-related head and neck cancers who were tracked for recurrence for up to 3.5 years with imaging and fiber-optic nasopharyngeal endoscopy. The patients had the blood test before and during treatment and at post-treatment follow-up visits.
February 5, 2020
2020 02 05 22 27 6689 Head Neck 400
Todos gains U.S. lab, Videssa cancer tests via Provista deal
Provista has developed a line of protein-based blood tests for the early diagnosis of cancer. Its Videssa Breast blood test is commercially available for help in interpreting abnormal or difficult-to-interpret imaging findings. Tests based on the same technology are being developed for endometrial cancer, ovarian cancer, and cancers associated with HPV.
January 8, 2020
2020 01 09 22 46 7361 Business Deal Corporate 400
New HPV saliva test may speed detection of mouth, throat cancers
Investigators at Duke University, the University of California, Los Angeles (UCLA), and other institutions developed an acoustofluidic noninvasive technique that analyzes saliva for the presence of HPV type 16, the pathogenic strain that causes oropharyngeal cancers (OPCs). Their acoustofluidic platform detected OPC in the saliva of 80% of patients with cancer confirmed by tissue biopsies, reported co-lead investigator Tony Jun Huang, PhD, a professor of mechanical engineering and mechanical science at Duke, and colleagues.
December 17, 2019
2019 12 17 22 01 3945 Saliva Hpv Test Adj 20191217224828
Previous Page
Page 2 of 3
Next Page